In combination w/ cyclophosphamide as conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia.
Dosage/Direction for Use
Adult 0.8 mg/kg IV via central nervous catheter as 2-hr infusion 6 hrly for 4 consecutive days (total: 16 doses).
Special Precautions
Myelosuppression. Monitor hematologic status & blood count. History of seizure disorder or head trauma or patients on epileptogenic drugs. Prior RT or progenitor cell transplant. Pregnancy & lactation. Childn.
Adverse Reactions
Profound myelosuppression including granulocytopenia, thrombocytopenia, anemia. Fever, headache, asthenia, chills, pain, edema, allergic reaction, chest pain, inflammation at inj site, back pain, tachycardia, HTN, thrombosis, vasodilation; GI disturbances; metabolic disorders; insomnia, anxiety, dizziness, depression; resp disorders; rash, pruritus.
Sign Out
